OnKure Therapeutics, Inc. (OKUR)

Market Cap	137.10M +244.2%
Revenue (ttm)	n/a
Net Income	-61.85M
EPS	-1.94
Shares Out	40.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	281,890
Open	3.150
Previous Close	3.190
Day's Range	2.990 - 3.420
52-Week Range	2.010 - 5.380
Beta	0.73
Analysts	Strong Buy
Price Target	15.50 (+357.9%)
Earnings Date	Nov 4, 2026

About OKUR

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 45
• Stock Exchange: Nasdaq
• Ticker Symbol: OKUR
• Website: https://onkuretherapeutics.com

Analyst Summary

According to 6 analysts, the average rating for OKUR stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 357.90% from the latest price.

Price Target

$15.5

(357.90% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 11, 2026

Data Sources Report a data error